deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT01220895

Alternate Donor Study of Pre-Emptive Cellular Therapy (CMV-ACE/ASPECT)

A Prospective Phase II Study to Investigate the Efficacy and Safety of Pre-emptive Cytomegalovirus Adoptive Cellular Therapy in Patients Receiving Allogeneic Haematopoietic Stem Cell Transplant From an Unrelated Donor

Sponsor: Cell Medica Ltd

Conditions Cytomegalovirus Infection
Interventions CMV-specific T-cells, single infusion following single positive CMV PCR result
Updated 6 times since 2017 Last updated: Jan 23, 2018 Started: Oct 31, 2010 Primary completion: Dec 31, 2013 Completion: Jan 31, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Cytomegalovirus Infection and is currently completed. Cell Medica Ltd leads this study, which shows 6 recorded versions since 2010 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Jan 2017 – ~Feb 2018 · 13 months · monthly snapshotCompleted~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Feb 2018 — Jun 2018 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2018 [monthly]

    Completed PHASE2

    First recorded

Oct 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Cell Medica Ltd
  • Leukaemia Lymphoma Research
  • National Health Service, Blood and Transplant
  • University of Birmingham
Data source: Cell Medica Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations